Genmab (GMAB)
(Real Time Quote from BATS)
$28.09 USD
+0.63 (2.29%)
Updated Apr 26, 2024 10:26 AM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GMAB 28.09 +0.63(2.29%)
Will GMAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
New Strong Buy Stocks for January 17th
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
GMAB or TECH: Which Is the Better Value Stock Right Now?
HRMY or GMAB: Which Is the Better Value Stock Right Now?
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
Other News for GMAB
Genmab Advances Share Buy-back Program
Genmab Acquires A Missing Piece For Its Pipeline
Genmab Reports Strong Q1 Sales of DARZALEX
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
J&J sets guidance below consensus as MedTech underperforms